At a glance
ClinicalIndex Comparison RecordN/ACompleted· 328 enrolled
Drug / intervention
No interventionother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A MULTI-CENTER, NON-INVASIVE OBSERVATIONAL STUDY OF METABOLIC SYNDROME PARAMETERS IN SCHIZOPHRENIC PATIENTS USING ATYPICAL ANTIPSYCHOTICS
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.·observational·Posted Mar 19, 2007·Updated May 3, 2022
In Brief
An observational study evaluating No intervention for Schizophrenia and Metabolic Syndrome X. Completed, enrolled 328 participants across 47 sites.
Detailed Summary
The purpose of the study is to find and follow-up the metabolic syndrome parameters on patients administering atypical antipsychotics.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia, Metabolic Syndrome X
CountriesTurkey (Türkiye)
Collaborators--
Timeline
N/ACompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 2007
Enrollment StartOct 2007
Primary CompletionJul 2008
TodayJul 2026
First PostedMar 19, 2007
Enrollment StartOct 23, 2007
Primary CompletionJul 30, 2008
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 19.3 years ago
Interventions
No interventionother
Non-interventional study